Yuanfei Ji
Yuanfei Ji has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bo Yu
Department of Orbital and Oculoplastic Surgery, Eye Hospital of Wenzhou Medical University, Wenzhou, China
1 shared publication - Guo-Gang Lai
Department of Neurology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, People’s Republic of China
1 shared publication - Guomin Xie
Department of Neurology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo University, Ningbo, China
1 shared publication - Haifeng Wang
Department of Neurology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, People’s Republic of China
1 shared publication - Hao Wu
Ningbo Institute of lnnovation for Combined Medicine and Engineering, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China
1 shared publication - Li-Li Huang
Ningbo Medical Center Li-Huili Hospital
1 shared publication
Latest Publications
- Open Access
- 16 February 2023
- Published by Springer Nature in Research Square
Recurrent anti-N-methyl-D-aspartate receptor encephalitis followed by anti-myelin oligodendrocyte glycoprotein encephalitis-a case report
Background Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is an autoimmune disease of the central nervous system (CNS) that often causes a range of neuropsychiatric symptoms; but with a relatively low recurrence rate. Anti-NMDAR encephalitis may occur with anti-myelin oligodendrocyte glycoprotein (MOG) encephalitis simultaneously or followed by anti-MOG encephalitis after several months. Case presentation We presented a case of recurrent anti-NMDAR encephalitis followed by anti-MOG encephalitis. A 39-year-old man was admitted to the hospital with five episodes of convulsive seizures, psychoses and memory deficits. With a positive Anti-NMDAR antibody in the cerebrospinal fluid (CSF), after being treated with intravenous immunoglobulins (IVIG) 22.5 g/day for 7 days, intravenous methylprednisolone pulse (IVMP) 500 mg/day for 4 days, and followed by IVMP 250 mg/day for 3 days, the patient was recovered completely. After 1 month, the patient developed disturbances of consciousness, speech difficulties and convulsions. With the positive result of Anti-NMDAR antibodies in the CSF again, we confirmed the diagnosis of recurrent anti-NMDAR encephalitis. The patient was then fully recovered after treatment with IVIG, IVMP and rituximab. Six months later, the patient was readmitted to the hospital with occasional convulsions. With a positive serum MOG antibody and a lesion in the right brainstem by brain magnetic resonance imaging (MRI), the patient was confirmed for anti-MOG encephalitis. The patient was fully recovered again after treatment with IVMP and rituximab, with no neurological sequels remained. Conclusion Patients with positive MOG antibodies are more likely to have brainstem MRI lesions than those with anti-NMDAR encephalitis. Rituximab is recommended for recurrent anti-NMDAR and anti-MOG encephalitis.
- 16 February 2023
- Published by Springer Nature in Research Square
Open AccessRecurrent anti-N-methyl-D-aspartate receptor encephalitis followed by anti-myelin oligodendrocyte glycoprotein encephalitis-a case report
Background Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is an autoimmune disease of the central nervous system (CNS) that often causes a range of neuropsychiatric symptoms; but with a relatively low recurrence rate. Anti-NMDAR encephalitis may occur with anti-myelin oligodendrocyte glycoprotein (MOG) encephalitis simultaneously or followed by anti-MOG encephalitis after several months. Case presentation We presented a case of recurrent anti-NMDAR encephalitis followed by anti-MOG encephalitis. A 39-year-old man was admitted to the hospital with five episodes of convulsive seizures, psychoses and memory deficits. With a positive Anti-NMDAR antibody in the cerebrospinal fluid (CSF), after being treated with intravenous immunoglobulins (IVIG) 22.5 g/day for 7 days, intravenous methylprednisolone pulse (IVMP) 500 mg/day for 4 days, and followed by IVMP 250 mg/day for 3 days, the patient was recovered completely. After 1 month, the patient developed disturbances of consciousness, speech difficulties and convulsions. With the positive result of Anti-NMDAR antibodies in the CSF again, we confirmed the diagnosis of recurrent anti-NMDAR encephalitis. The patient was then fully recovered after treatment with IVIG, IVMP and rituximab. Six months later, the patient was readmitted to the hospital with occasional convulsions. With a positive serum MOG antibody and a lesion in the right brainstem by brain magnetic resonance imaging (MRI), the patient was confirmed for anti-MOG encephalitis. The patient was fully recovered again after treatment with IVMP and rituximab, with no neurological sequels remained. Conclusion Patients with positive MOG antibodies are more likely to have brainstem MRI lesions than those with anti-NMDAR encephalitis. Rituximab is recommended for recurrent anti-NMDAR and anti-MOG encephalitis.
- Open Access
- 30 December 2021
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 32 (5) , 2589-2597
The change of microglia numbers within the mice retina, optic nerve and chiasm following intravitreal AAV2-GFP injection
Purpose: To explore the optimized concentration of AAV2-GFP for sparse transfection of retinal ganglion cells (RGCs) and optic nerve (ON), and to examine the changes of microglial morphology and distribution in the retina, optic nerve and chiasm after injection. Methods: We defined the optimal concentration of AAV2-GFP for sparse labeling of RGCs and axons in WT mice. We further explored the changes of microglial morphology and distribution in the retina, optic nerve and chiasm after intravitreal injection in CX3CR1+/GFP mice. Results: 14 days after intravitreal injection of AAV2-GFP, live imaging of the retina showed that fundus fluorescence was very strong and dense at 2.16 × 1011 VG/retina, 2.16 × 1010 VG/retina, 2.16 × 109 VG/retina. RGCs were sparsely marked at a concentration 1:1000 (2.16 × 108 VG/retina) and fundus fluorescence was weak. The transfected RGCs and axons were unevenly distributed in the retina and significantly more RGCs were transfected near the injection site of AAV2-GFP compared to the other sites of the flat-mounted retina. Microglia density increased significantly in the retina and part of optic nerve, but not in the optic chiasm. The morphology of microglia was largely unchanged. Conclusions: AAV2-GFP was highly efficient and the optimal concentration of sparsely labeled RGCs was 1:1000 (2.16 × 108 VG/retina). After intravitreal injection of AAV2-GFP, the number of microglia increased partly. The morphology of microglia was comparable.
- 30 December 2021
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 32 (5) , 2589-2597
Open AccessThe change of microglia numbers within the mice retina, optic nerve and chiasm following intravitreal AAV2-GFP injection
Purpose: To explore the optimized concentration of AAV2-GFP for sparse transfection of retinal ganglion cells (RGCs) and optic nerve (ON), and to examine the changes of microglial morphology and distribution in the retina, optic nerve and chiasm after injection. Methods: We defined the optimal concentration of AAV2-GFP for sparse labeling of RGCs and axons in WT mice. We further explored the changes of microglial morphology and distribution in the retina, optic nerve and chiasm after intravitreal injection in CX3CR1+/GFP mice. Results: 14 days after intravitreal injection of AAV2-GFP, live imaging of the retina showed that fundus fluorescence was very strong and dense at 2.16 × 1011 VG/retina, 2.16 × 1010 VG/retina, 2.16 × 109 VG/retina. RGCs were sparsely marked at a concentration 1:1000 (2.16 × 108 VG/retina) and fundus fluorescence was weak. The transfected RGCs and axons were unevenly distributed in the retina and significantly more RGCs were transfected near the injection site of AAV2-GFP compared to the other sites of the flat-mounted retina. Microglia density increased significantly in the retina and part of optic nerve, but not in the optic chiasm. The morphology of microglia was largely unchanged. Conclusions: AAV2-GFP was highly efficient and the optimal concentration of sparsely labeled RGCs was 1:1000 (2.16 × 108 VG/retina). After intravitreal injection of AAV2-GFP, the number of microglia increased partly. The morphology of microglia was comparable.